Analysts start to sort out which biopharma companies’ R&D plans are most threatened by a pandemic
With the pandemic capturing headlines around the world, one of the big questions in biopharma is whether or not the inevitable disruptions caused by the outbreak will ripple — or tear — through drug R&D plans.
So far, there have been few reports of any interruptions in clinical trials outside of China, where the hospital-based system of drug research is taking an obvious beating as people steer clear of hospitals. But the prospect that the pandemic will inevitably have an impact is hard to ignore.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,600+ biopharma pros reading Endpoints daily — and it's free.